NasdaqCM - Nasdaq Real Time Price USD

Citius Pharmaceuticals, Inc. (CTXR)

0.5451 -0.0123 (-2.21%)

At close: November 6 at 4:00:01 PM EST

0.5949 +0.0498 (+9.14%)

After hours: November 6 at 4:25:26 PM EST

Loading Chart for CTXR

Chart Range Bar

Interval:

In partnership with ChartIQ

Citius Pharmaceuticals to Participate in October 2026 Investor Conferences

Is Citius Pharmaceuticals, Inc. (CTXR) among the Best Rated Penny Stocks to Buy According to Wall Street Analysts?

Citius Pharmaceuticals Announces Closing of Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules

Citius Pharmaceuticals Secures $5M Through Equity Offering

Citius Pharmaceuticals Announces a Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules

We Might See A Profit From Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Soon

Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri

Citius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical Development

$Citius Oncology's Positive Quality of Life Data for LYMPHIR® (denileukin diftitox-cxdl) in Relapsed or Refractory Cutaneous T-Cell Lymphoma Presented at Premier Global CLTG Congress in Europe$

Citius Oncology's Positive Quality of Life Data for LYMPHIR® (denileukin diftitox-cxdl) in Relapsed or Refractory Cutaneous T-Cell Lymphoma Presented at Premier Global CLTG Congress in Europe

Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR® Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026

U.S. markets open in 2h 38m